Adaptive Biotechnologies Corp
ADPTQ1 2024(ADPT Q4 FY2023)Estimated8% AI
AI Revenue %
8%
AI Fair Value
$78.3M
AI Revenue (Q)
$3.0M
Total Revenue (Q)
$37.9M
Source: SEC EDGAR 10-K Filing
View 10-K on SEC.govAnalysis
FY2023 implied revenue: 9-month $124.5M, FY total implied ~$166.2M, so Q4 ~$41.7M. No segment data available for Q4 2023 specifically. Based on Q1 2024 segment data showing IM at $9.2M/$41.9M = 22%, and applying 50% AI attribution to IM: ~11%. However, Q4 2023 was pre-segment reporting and IM run rate appears lower in 2023. Using 8% conservatively.
Analyzed by claude-opus-4-6
Quoted Figures
Nine months ended September 30, 2023 revenue $124,492K; FY2023 implied ~$166M
10-Q filed 2023-11-07 and 10-K FY2023
AI Products Identified (Ring 1)
Immune Medicine TCR-Antigen MapAdaptive Immunosequencing
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic testMRD Pharma testing services
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix